Abstract | For over 100 years, clinicians and scientists have been unravelling the consequences of the A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the systemic manifestations of sickle cell disease (SCD), including vaso-occlusion, anaemia, haemolysis, organ injury and pain. However, despite growing understanding of the mechanisms of haemoglobin S polymerization and its effects on red blood cells, only two therapies for SCDhydroxyurea and l-glutamine -are approved by the US Food and Drug Administration. Moreover, these treatment options do not fully address the manifestations of SCD, which arise from a complex network of interdependent pathophysiological processes. In this article, we review efforts to develop new drugs targeting these processes, including agents that reactivate fetal haemoglobin, anti-sickling agents, anti-adhesion agents, modulators of ischaemiareperfusion and oxidative stress, agents that counteract free haemoglobin and haem, antiinflammatory agents, anti-thrombotic agents and anti-platelet agents. We also discuss gene therapy , which holds promise of a cure, although its widespread application is currently limited by technical challenges and the expense of treatment. We thus propose that developing systemsoriented multi-agent strategies on the basis of SCD pathophysiology is needed to improve the quality of life and survival of people with SCD.
. This often devastating disease is characterized by red blood cell (RBC) sickling; chronic haemolytic anaemia; episodic vaso-occlusive crises (VOCs) that are associated with severe pain and inflammation; acute and cumulative organ damage that manifests as stroke, a pneumonia-like syndrome termed acute chest syndrome (ACS), sickle lung disease, pulmonary hypertension, nephropathy and end-stage renal disease; and other chronic morbidities 3 . Not surprisingly, patients with SCD have very high health-care utilization (over $1 billion per year in healthcare costs in the United States alone) 4 and a median life expectancy of only ~45-58 years, compared with the life expectancy of 78 years overall in the United States 3, 5 . The pathophysiology of SCD arises from a single amino acid alteration in adult haemoglobin (Hb), the expression of which is primarily limited to RBCs. Nonetheless, the effects of the causative mutation are far reaching, mediated by the interacting processes of haemolysis and aberrant RBC behaviour in the circulation. In this Review, we first highlight the complex and multifaceted pathophysiological networks in SCD.
We then review progress so far on the various strategies that have been used to intervene therapeutically in these networks, including agents that induce haemoglobin F (HbF), anti-sickling agents, modulators of ischaemia-reperfusion injury and oxidative stress, anti-inflammatory agents, therapies to counteract free Hb and haem, anti-thrombotic therapies, anti-platelet therapies and anti-adhesion agents. We focus on agents that are currently either in clinical evaluation or have strong translational potential, while also noting lessons learned from failures of agents that are no longer being actively investigated. We also summarize emerging gene therapy approaches, including therapeutic gene transfer with lentiviral vectors and gene editing, which have the potential to be curative. Nevertheless, such therapies are still at an early stage of development, and their likely costs could limit access in many countries in which SCD is most prevalent. We therefore suggest that systemsoriented strategies based on the use of multiple agents with different targets will have a key role in improving the treatment of SCD, and we discuss challenges in the development of such strategies. Haematopoietic stem cell (HSC) transplantation from a healthy donor is an established curative therapy for SCD [6] [7] [8] [9] [10] [11] but is limited
Therapeutic strategies for sickle cell disease: towards a multi-agent approach to 10-20% of patients with SCD with an appropriately matched donor and is not the focus of this Review.
Pathophysiology of SCD
The pathological single amino acid substitution (Glu to Val) at the sixth position of the β-chain of haemoglobin S (HbS) results in a loss of negative charge and a gain in hydrophobicity that alters Hb dimer-tetramer assembly (Box 1), resulting in HbS instability and polymerization 12 . Following deoxygenation of HbS, deoxyHbS aggregates densely pack into polymers, and the RBC changes shape ('sickles') owing to this polymerinduced distortion (Fig. 1a) , giving the disease its name. This distortion is the fundamental basis for the haemolytic anaemia, vaso-occlusion associated with painful events, organ dysfunction and shortened lifespan in people with SCD. However, this simple human Hb defect leads to a plethora of downstream effects, each of which sets in motion a particular pathophysiological pathway, as described below. Figure 1a outlines how the oxidative biochemistry of HbS and the sickle RBC (SRBC) can lead to a variety of cellular and membrane abnormalities that contribute to the pathophysiology of SCD. Figure 1b proposes that these oxidative changes in the SRBC promote haemolysis, depletion of nitric oxide (NO), excess reactive oxygen species (ROS) and endothelial activation.
The adhesion of SRBCs along with white blood cells (WBCs) and platelets leads to vaso-occlusion in the postcapillary venules, causing hypoxia, sickling and ultimately organ damage. The depletion of scavengers of free Hb and haem, haptoglobin and haemopexin, worsens the pro-inflammatory, pro-adhesive and procoagulant environment within the vessel wall. Ultimately, flow is restored and ischaemia-reperfusion pathophysiology with activation of xanthine dehydrogenase to xanthine oxidase can occur to promote more ROS production 13, 14 .
Haemolysis. It is estimated that about one-third of haemolysis in SCD is intravascular, owing to mechanical destruction of deformed and inelastic SRBCs, whereas two-thirds is extravascular, resulting from removal of abnormal SRBCs by the reticuloendothelial system 15 . The consequences of haemolysis include the immediate effects of RBC loss, such as anaemia and expansion of erythropoiesis with increased reticulocytosis. Haemolysis also releases Hb from RBCs or RBC microparticles into the plasma, leading to increased levels of toxic haem. Increased haem levels associated with chronic haemolysis cause depletion of plasma haptoglobin and haemopexin, which tightly bind haem. Haemolysis, membrane alterations and their downstream effects also appear to promote decreased NO bioavailability; haemostatic system abnormalities; production and release of vasoactive agents; increased erythrocyte, leukocyte and platelet adhesion and activation; increased endothelial cell activation and injury; iron overload; vaso-occlusion; inflammation; and ischaemia-reperfusion injury 16 .
Adhesion and coagulation.
SRBCs have increased expression and activation of various signaltransducing proteins, including ones belonging to the β 2 -adrenergic-Gα i protein-adenylyl cyclase-protein kinase A and MAPK pathways 17, 18 . Both of these pathways activate the normally inactive erythroid adhesion molecules Lutheran/basal cell adhesion molecule (Lu/ BCAM), intercellular adhesion molecule 4 (ICAM4) and CD44 as well as the NADPH oxidase (NOX) pathways 19 , which increase oxidant stress. Thus, SRBCs not only adhere to the endothelium but also interact with circulating and stationary leukocytes and platelets [20] [21] [22] [23] [24] [25] [26] . Activation of circulating leukocytes and platelets further exacerbates the propensity to develop vaso-occlusion, and leukocytes that adhere to the endothelium readily 'capture' circulating SRBCs. Adhesion of SRBCs also promotes expression of pro-adhesive and procoagulant proteins on the surface of endothelial cells 27 . Damage to RBC membranes and alteration of cytoskeletal proteins, probably through reversible HbS polymerization, oxidant injury and aggregation of proteins along the inner membrane leaflet, also result in poorly deformable RBCs that can be trapped in vessels, best seen in the spleen in children, independently of polymerized HbS 28 . The coagulation system is hyperactivated in SCD. Although any process that increases adhesion of SRBCs or leukocytes to endothelial cells can cause microvascular occlusion and promote stasis-induced microthrombi owing to coagulation activation, SRBC intrinsic and
Box 1 | Haemoglobin composition and function
Human haemoglobin (Hb) is a metalloprotein that possesses a quaternary structure. The quaternary structure is derived from four globular protein subunits. The most common combination of globular protein subunits is called haemoglobin A (HbA) and consists of two α-globin subunits encoded on chromosome 16 and two β-globin subunits encoded on chromosome 11. each monomer is attracted electrostatically to unlike monomers to form α-β dimers and ultimately assemble as an α 2 β 2 tetramer to optimally bind oxygen, forming HbA (α 2 β 2 ; see figure) . HbA is the dominant Hb variant in healthy adults and accounts for roughly 97% of all Hb.
The presence of haemoglobin S (HbS; α 2 β S 2 ) -a variant form of Hb with a glutamic acid to valine substitution at position 6 that results from a GAG to GTG mutation in the β-globin gene (HBB) -underlies sickle cell disease (SCD). upon deoxygenation, HbS polymerizes into a semisolid crystalline-like polymer structure that is reversible with oxygenation. This property of HbS is responsible for the familiar shape change of the red blood cell to sickle or hook shapes owing to the sickle polymer-induced distortion. other SCD genotypes are possible, including a β S allele combined with a null HBB allele (Hbβ 0 ), which causes HbSβ 0 -thalassaemia. variations in the subunit composition of Hb also occur during development. The main form of human Hb during fetal development until approximately 6 months of age contains two α-globin subunits and two γ-globin subunits and is known as haemoglobin F (HbF; α 2 γ 2 ). In early life, expression of the gene coding for the γ-globin subunit is repressed and HbA becomes the dominant form in healthy individuals, whereas HbS is produced in patients with sickle cell disease. As discussed further in the text, however, reactivation of HbF can be achieved pharmacologically, and this is useful in patients with SCD because the stronger negative charge of γ-globin allows it to outcompete β S -globin for α-globin, leading to the formation of HbF rather than HbS. Upon deoxygenation of haemoglobin S (HbS), deoxygenated HbS aggregates densely into polymers, and the RBC changes shape ('sickles') owing to this polymer-induced distortion. Spontaneous auto-oxidation of HbS Fe(II) leads to the formation of Fe(III)-methaemoglobin (HbFe(III)) and release of haem from the globin. O 2 is reduced to superoxide, which is converted to hydrogen peroxide (H 2 O 2 ) by superoxide dismutase (SOD) 19 . A catalytic cycle between ferric HbFe(III) and the ferryl HbFe(IV) can be initiated by H 2 O 2 (reF.
220
), which is subsequently eliminated in a pseudoperoxidase-like manner. Ferryl Fe(IV) HbS promotes βCys93 oxidation, haemoglobin (Hb) dimerization and hemichrome formation. Upregulated NADPH oxidase 19 contributes to the oxidative environment, as do downregulated oxidative defence pathways 221 . Sickle RBCs also have retained mitochondria 222 , providing another source of oxidants that lead to membrane damage. There is a decrease in glutathione as well as reduced activity of glutathione peroxidase, vitamin E, catalase and peroxiredoxin. Oxidative membrane protein and lipid changes, including phosphatidylserine (PS) expression on the membrane, promote erythrophagocytosis, adhesion, complement activation and prothrombinase assembly. Excess oxidants lead to band 3 sulfhydryl oxidation; increased erythrophagocytosis; altered Na + , Ca 2+ and K + homeostasis; dehydration; mechanosensitivity and deformability ; increased fragility and vesiculation of microvesicles (which contain HbS and haem); increased activity of adhesion receptors on the RBC membrane; and haemolysis. b | Haemolysis results in several intravascular events promoting vaso-occlusion in sickle cell disease (SCD). The abnormal sickle RBC membrane changes ultimately lead to haemolysis within the vasculature and the release into the plasma of Hb, reactive oxygen species (ROS) and arginase 223 , which can accentuate nitric oxide (NO) depletion in the plasma. Free Hb can react with NO and can readily oxidize to MetHb; ROS can activate the endothelium of the vessel wall to promote adhesion molecule expression and the adherence of sickle RBCs, white blood cells (WBCs) and platelets. Within the vessel, free MetHb readily gives up its haem 47 , which can interact with inflammatory cells and the endothelium. Excess plasma Hb and haem deplete the haem scavengers haptoglobin and haemopexin 224 . The adhesion of sickle RBCs, WBCs and platelets slows the flow in postcapillary venules, leading to further sickle RBC deoxygenation, sickling and vaso-occlusion 225 .
NATuRe RevIeWS | Drug DiSCOvery extrinsic abnormalities themselves can activate the coagulation system and platelets. Phosphatidylserine (PS) externalization is commonly seen in SRBCs and in sickle reticulocytes 29 and occurs secondary to increased oxidative stress 30 , increased intracellular calcium induced by sickling and cellular dehydration 31 . More recently, it was shown that PS exposure may be a normal developmental process in immature reticulocytes undergoing autophagy, and the autophagic vesicles are removed by the spleen. However, owing to trapping of abnormal RBCs in the spleen, patients with SCD have hypofunctional and eventually autoinfarcted spleens. Hyposplenia and eventual functional asplenia amplify the risk of infection by encapsulated bacteria and result in increased levels of circulating mature reticulocytes expressing inside-out PS-exposed autophagic vesicles 32 . All of these contribute to a hypercoagulable state primarily induced by PS-expressing sickle reticulocytes and SRBCs that increase thrombogenesis and promote adhesion 32 .
Patients with SCD show high plasma levels of coagulation factors involved in thrombin generation [33] [34] [35] [36] . In support of these clinical findings, a sickle mouse with genetically imposed reduction in thrombin showed significantly improved organ pathology 36 . In addition, chronic platelet activation and aggregation is observed in patients with SCD, which is evident by the expression of platelet activation markers 21, 33 . Platelet agonists such as thrombin, ADP and adrenaline are increased in the plasma of patients with SCD and contribute to platelet activation. Activated platelets release thrombospondin, which mediates adhesion of SRBCs to endothelial cells via both CD47 as well as CD36 -cell surface molecules present on both erythroid and endothelial cells 34 . CD40 and soluble CD40L, expressed on and shed by activated platelets in SCD, respectively, mediate increased coagulation. Ligation of CD40 on endothelial cells by CD40L increases tissue factor (TF) and ICAM1 expression 34, 37 . An increase in plateletmonocyte and platelet-neutrophil aggregates is also observed in patients and mouse models of SCD, which is postulated to be mediated via an interaction between the platelet integrin αIIbβ3 and fibrinogen 38 , although other lines of evidence point to a role for P-selectin in aggregate formation as well [39] [40] [41] [42] .
Oxidation and inflammation. Haem derived from
SRBCs can act as a damage-associated molecular pattern (DAMP) that activates Toll-like receptor 4 (TLR4) of the innate immune system, leading to oxidant production, inflammation, vaso-occlusion, ischaemia and tissue injury, including pulmonary injury 43, 44 . TLR4 ligation on the endothelium triggers exocytosis of Weibel-Palade bodies, which contributes to endothelial recruitment of leukocytes by increasing the expression of P-selectin, and promotes coagulation through release of von Willebrand factor (VWF) 45 . TLR4 signalling also activates the inflammasome in monocytes and macrophages via nuclear factor (NF)-κB. Scavenging Hb and haem with haptoglobin or haemopexin in sickle mice inhibits TLR4 activation and consequent vaso-occlusion. Excess Hb and haem are degraded by haem oxygenase 1 (HO1) with production of carbon monoxide (CO). Ferritinespecially ferritin heavy chain (FHC) with its ferroxidase activity -is insufficiently upregulated to handle the haem burden in patients with SCD, as evident in patients who have longer GT repeats and more frequent ACS and who would presumably make less HO1 in response to haem 46 . Increasing HO1 levels to degrade haem inhibits oxidative stress, inflammation, vaso-occlusion and organ pathology in SCD mice 47 . Interconnection in SCD pathophysiology. As described above, SCD pathophysiology involves multiple processes, primarily affecting RBCs but also other blood cells, the vasculature and multiple biological pathways 14 . Vaso-occlusion and haemolysis are interrelated, amplifying each other and promoting the production of a myriad of biological mediators. Slow microvascular transit resulting from adhesive interactions and reduced RBC deformability increases deoxygenation, polymerization, sickling, adhesion and vaso-occlusion 12 . Ischaemiareperfusion injury, caused by vaso-occlusion followed by reperfusion, probably occurs in every organ of patients with SCD 13 . In addition, SRBCs and monocytes directly activate adhesivity of both leukocytes and endothelial cells 42 . These constant stimuli of inflammation and underlying systemic endothelial dysfunction represent a vicious circle, with increased RBC, WBC, platelet and endothelial cell adhesion promoting slower flow and thus further deoxygenation, HbS polymerization, sickling, stasis, haemolysis and release of Hb and free haem, as well as more vascular occlusion, followed by reperfusion and more inflammation. This pro-inflammatory and pro-oxidative milieu is a critical contributor to the leukocytosis, WBC activation, acute phase reactants, cytokine elevation, excess oxidants, increased expression and activation of adhesion molecules by all blood cells, endothelial activation, dysfunction, aberrant vaso-regulation, decreased NO bioavailability and coagulation activation, all of which ultimately result in multi-organ injury and pain in patients with SCD. These interconnected pathophysiologies are illustrated in Fig. 2 .
Developing new SCD therapies
Given the complexity of SCD pathophysiology, multiple therapeutic strategies have been pursued. To date, at least some progress has been made on most of the key fronts noted in the introduction of the article, which we review below and summarize in TaBles 1-6. We also examine progress with potentially curative gene therapy approaches, some of which are already in clinical trials. However, these approaches will not be at the forefront of treatment options for some time, especially as their application in countries with the highest numbers of people with SCD may be limited by their technical demands and cost. Consequently, we propose that a systems-oriented multi-agent approach targeting several aspects of the pathophysiological process in SCD should be pursued, and we discuss the challenges for this strategy. General challenges for drug development for SCD are highlighted in Box 2.
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Pharmacological reactivation of HbF. HbF has long been known to retard the polymerization of HbS 48 . Indeed, infants with SCD are not symptomatic until their HbF production declines, and patients with SCD with hereditary persistence of HbF have a mild disease phenotype, characterized by fewer VOCs, less cumulative organ damage and longer survival (reviewed in reFs 3, 49 ) . Clinical studies have shown that a threshold of 10% HbF reduces major organ damage, whereas 20% HbF results in amelioration of VOC and pulmon ary complications in SCD 50, 51 . Consequently, reacti va tion of HbF has been a major focus of both drug development and gene therapies (discussed separately in a later section).
Chemotherapeutic agents that impose regenerative haematopoietic stress increase HbF production in erythrocytes. One of the first chemotherapeutic drugs used to reactivate HbF was the DNA methyltransferase (DNMT) inhibitor 5-azacytidine, which has DNA-hypomethylating activity [52] [53] [54] . However, it was quickly abandoned owing to its toxicity and carcinogenicity. Next, the chemotherapeutic drug hydroxyurea, a ribonucleotide reductase inhibitor without DNA-hypomethylating activity that has a known longterm safety profile in myeloproliferative diseases, was shown to reactivate HbF production. Its mechanism of action in SCD is still unclear, but it is thought to involve cytotoxicity-induced stress erythropoiesis. The expression of HbF with hydroxyurea is generally heterocellular. In 1998, hydroxyurea became the first drug to be licensed by the US Food and Drug Administration (FDA) for adults with SCD, and its use has led to a reduction of complications of SCD in adults, children and even infants, as well as prolonged survival 55 . However, because hydroxyurea does not improve HbF production in all patients, requires regular monitoring of blood counts and has intolerable side effects in some patients, many alternative HbF-inducing agents have been explored. Molecular studies of globin gene regulation have identified the γ-globin repressor protein complex: TR2 and TR4 nonsteroidal nuclear receptor proteins specifically bind to γ-globin regulator elements and subsequently recruit a multi-protein co-repressor complex that includes DNMT1, lysinespecific demethylase 1 (LSD1; also known as KDM1A) and histone deacetylases (HDACs), BCL-11A and SOX6 to repress gene expression. Hence, drugs targeting repressive complex proteins have been explored (summarized in TaBle 1) .
Decitabine was found to be a potent inhibitor of DNMT1 and to have a more favourable safety profile than 5-azacytidine. The oral formulation of decitabine, however, is rapidly deaminated by cytosine deaminase and inactivated; when given with a cytosine deaminase inhibitor, tetrahydrouridine, this limitation is overcome. This combined therapy was tested in a phase I trial (NCT01375608) that showed HbF increased by 4-9% and doubling of HbF-enriched RBCs (F-cells) up to ~80% of total RBCs. Importantly, this agent does not induce cytoreduction but increases platelet counts, and although this was not dose limiting in this early-phase study, it may become problematic in SCD. A trial is ongoing (NCT01685515) and results are awaited 56 . Another category of HbF-inducing agents that have been studied clinically are HDAC inhibitors. Arginine butyrate, a short-chain fatty acid, was shown to increase HbF in pulsed parenteral dosing 57 , although its oral formulations had only modest effects. Several different 
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isoforms of HDAC are present, and it is not surprising that global HDAC inhibition with butyrates was associated with toxicities, and a pulsed or intermittent dosing regimen was necessary to avoid cytotoxicity. Another oral short-chain fatty acid derivative, sodium HbF, haemoglobin F; HDAC, histone deacetylase; mTOR , mechanistic target of rapamycin; NO, nitric oxide; RBC, red blood cell; ROS, reactive oxygen species; SCD, sickle cell disease; TLR4, Toll-like receptor 4; TNF, tumour necrosis factor ; VOC, vaso-occlusive crisis; WBC, white blood cell.
NATuRe RevIeWS | Drug DiSCOvery above baseline in SCD (NCT01322269) 58 . However, the double-blind phase II trial showed minimal to modest increases in HbF in 24% of patients (NCT01601340) 59 . Suberoylanilide hydroxamic acid (vorinostat), an orally available HDAC inhibitor that is approved for the treatment of cutaneous T cell lymphoma, showed efficient HbF induction in vitro and was tested in a phase I/II trial in SCD (NCT01000155). However, the trial was closed owing to insufficient enrolment. In general, clinical and investigational HDAC inhibitors have been limited by non-class-specific HDAC inhibitionassociated toxicities. Using small hairpin RNA-based knockdown of HDAC1-HDAC9 showed that knockdown of HDAC1/HDAC2 improved HbF without global histone acetylation. A small molecule (LBH589; panobinostat) that inhibits these HDAC isoforms at low concentrations was shown to improve HbF in three patients treated for Hodgkin lymphoma 60 . Following this, a trial of panobinostat was initiated in SCD (NCT01245179) and is anticipated to be completed in 2019. Overall, studies on HDAC inhibition have shown that the toxicities of global HDAC inhibitors, especially with lifelong use, undermined their translation into effective HbF-inducing therapies; specific HDAC1/ HDAC2 inhibitors with no effect on global acetylation may have potential.
Thalidomide derivatives have also been tried (shown in TaBle 1 ). Other agents that inhibit the γ-globin repressor protein complex, specifically LSD1, show great promise. Tranylcypromine (TCP), an LSD1 inhibitor, was shown to induce HbF in vitro and in mice 61 . Because TCP has known side effects that preclude its use in SCD, a more potent and specific LSD1 inhibitor, RN-1, was investigated and found to increase HbF in sickle mice 62 . It has also been tested in baboons, in which it showed strong HbF induction 63 , although one concerning effect was neutropenia and thrombocytopenia. The LSD1 inhibitor INCB059872 is in a phase I trial (NCT03132324).
Finally, metformin, a FOXO3 inducer, has been shown to increase HbF production in erythroid cells in vitro and is now being tested in patients with SCD (NCT02981329). Other promising HbF-reactivating agents currently in preclinical studies include recombinant SIRT1 (reF.
64
), a hydroxyurea-thalidomide hybrid 65 , resveratrol 66 and dimethyl fumarate 67 . ; warfarin showed modest reduction in VOC from 1.3 VOCs per year to 0.9 VOCs per year in one small study 130 ; acenocoumarol reduced markers of coagulation activation but did not affect frequency of VOCs 261 
Heparin
Anti-thrombin Mini-dose heparin for 2-6 years showed ~70% reduction in VOC hospitalizations or emergency department visits in one small study 132 Low-molecular-mass heparins Anti-thrombin One large phase II study showed reduction in VOC duration 133 ; a smaller randomized study of dalteparin (NCT01419977) showed reduction in d-dimer and thrombin generation as well as pain scores 262 
Rivaroxaban and apixaban

Factor Xa inhibitors
Randomized placebo-controlled trials underway (NCT02072668 and NCT02179177)
NSAID, nonsteroidal anti-inflammatory drug; RBC, red blood cell; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
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Overall, with better understanding of the molecular regulation of globin gene switching, key repressors such as BCL-11A, SOX6, MYB, KLF1, TR2/TR4, HDAC1/ HDAC2 and LSD1 have been identified, with BCL-11A identified as a major repressor of HbF. Compounds that target these with specificity hold the potential to translate to more potent and less toxic HbF inducers.
Anti-sickling agents. Hb polymerization and subsequent cell 'sickling' are promoted by HbS deoxygenation and higher Hb concentrations. Therefore, agents that shift the oxygen-dissociation curve or otherwise push the conformation of HbS to the R (oxygenated) state will reduce Hb polymerization and cell sickling, resulting in a reduction of haemolysis and improvement in anaemia (Fig. 1a) . Other less well-characterized chemicals that influence Hb conformation may also affect Hb polymerization and cell sickling (TaBle 1) .
One anti-sickling approach that has been tested is to deliver CO to HbS. CO in low concentrations may act to prevent sickling, haemolysis and vaso-occlusion through multiple mechanisms, including a direct effect on Hb conformation, inhibition of dehydration through the Ca 2+ -permeable cation conductance channel, antioxidant effects and anti-inflammatory effects through HO1 and NRF2 (a transcriptional regulator of several antioxidant enzymes; also known as NFE2L2) 68 . In sickle mice, an infusion of pegylated carboxyhaemoglobin (MP4CO) improved vascular stasis in response to hypoxia-reperfusion through an HO1-dependent mechanism. MP4CO also induced NRF2 and inhibited NF-κB activation 69 . MP4CO successfully completed a phase I study in patients with SCD in steady state without major safety concerns 70 , but development of this agent has since been discontinued for undisclosed reasons.
A somewhat similar product, pegylated bovine carboxyhaemoglobin (PEG-bHb-CO), has been proposed to both release CO and transfer oxygen to Hb. In animal models of various types of ischaemia, infusion of PEGbHb-CO was able to reduce tissue damage and promote recovery 71 . In early-phase human studies, this agent has been judged safe in both healthy and steady-state SCD subjects 72 . A phase II randomized, single-blind study of the drug in patients with SCD experiencing vasoocclusive episodes is now underway (NCT02672540). PEG-bHb-CO is also being studied in other conditions involving severe anaemia and tissue damage.
SCD-101 is an oral botanically derived drug that has an anti-sickling effect in vitro, albeit by an unknown mechanism 73 . A similar preparation, NIX-0699 (Niprisan; Xechem International), was developed from a combination of African plants as an herbal medicine and has been shown to significantly prolong the delay time before polymerization (that is, the length of the delay until polymer forms owing to the conversion of HbS from R (oxy) to T (deoxy) states) 12 , although it has only a minor effect on the oxygen-dissociation curve 74 . NIX-0699 was reported to be safe and effective in reducing the frequency of vaso-occlusive symptoms in a phase II study in Africa 75 . A phase Ib two-part study of SCD-101 (NCT02380079), comprising a nonrandomized doseescalation phase followed by a randomized, placebocontrolled, crossover study, is currently ongoing in the United States.
Voxelotor (GBT-440) is another oral anti-sickling drug under development and currently has both FDA Fast Track and Orphan Drug designations. This compound forms a reversible covalent bond to the amino terminus of the Hb α-chain, thereby stabilizing HbS in the oxy-Hb conformation. As reported in abstract form, GBT-440 treatment for up to 6 months in 41 patients with SCD resulted in haematological responses, including increased Hb and decreased reticulocytes and/or bilirubin 76 . Slightly less than half of treated patients Haptoglobin Clears free haemoglobin via CD163 (reF.
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) Decreased inflammation in SCD mice 45, 272 Haemopexin Clears haem via CD91 Decreased TLR4 signalling in SCD mice 44, 45, 117, 273 Iron chelators Bind and clear excess iron; decrease oxidative stress
Decreased inflammation and VOCs in SCD mice 45, 239 CO, carbon monoxide; HO1, haem oxygenase 1; NO, nitric oxide; TLR4, Toll-like receptor 4; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
NATuRe RevIeWS | Drug DiSCOvery experienced a clinically meaningful Hb increase of >1 g dl -1 . A phase III, double-blind, randomized, placebocontrolled, multicentre study of GBT-440 in SCD (NCT03036813) is now underway in the United States. Nonetheless, there remain at least some concerns that treatments that shift Hb oxygen affinity may bring significant risks to cerebrovascular oxygenation 77 . GBT-440 and other agents with similar effects on Hb decrease the oxygen-carrying capacity of Hb and thus have been theorized to have potential negative effects on tissues with especially high oxygen demand, such as the brain and kidney 77 . However, data presented to date have not shown evidence of adverse effects due to decreased oxygen availability to such organs.
Modulators of ischaemia-reperfusion injury and oxidative stress.
In SCD, ischaemia-reperfusion physiology -caused by the transient vaso-occlusion followed by the opening of vessels to re-establish flowseems to lead to increased oxidant production (Fig. 1b) .
The conversion of xanthine dehydrogenase to xanthine oxidase in tissues results in the production of super oxide anion and hydrogen peroxide. These ROS activate NF-κB, stimulating the production of inflammatory cytokines such as tumour necrosis factor (TNF), upregulating adhesion molecule expression and promoting leukocyte, platelet and procoagulant activation (TaBle 2) .
Glutamine and glutathione (GSH) levels have been found to be decreased in SRBCs. Moreover, RBC GSH depletion in SCD has been linked to haemolysis and oxidative stress 78 . Glutamine taken up by RBCs can be converted to glutamate by deamination and used as a precursor of GSH 79 . l-Glutamine therapy also reduces the endothelial adhesion of SRBCs to human endothelial cells 80 . Following a phase III randomized trial in SCD, in which oral l-glutamine therapy demonstrated clinical benefit, with reduced frequency of VOCs and hospitalizations over 6 months 81 , as well as decreased incidence of ACS, l-glutamine became only the second agent to be approved by the FDA for SCD in 2017 (reF.
82
).
A direct approach to reducing oxidative stress could also be to inhibit the production of ROS. Allopurinol is a xanthine oxidase inhibitor that is approved for the treatment of high uric acid levels derived from purine metabolism. One study of this drug in sickle mice showed no benefit in blunting blood cell-endothelial cell adhesion responses, whereas another suggested benefit with improved blood flow and decreased leukocyte recruitment 83, 84 . However, during ischaemia, purine triphosphates are released from cells, stoking these purine pathways. A trial in human SCD seems warranted, possibly performed in combination with other agents.
N-Acetyl cysteine (NAC) has been used to treat a variety of pro-oxidative injury states, such as acetaminophen toxicity. In SCD, providing enhanced sulfhydryl thiols using agents such as NAC to increase levels of amino-thiol GSH in RBCs and thereby decrease oxidative stress seems a promising strategy. An open-label pilot study of NAC treatment for 6 weeks in patients with SCD decreased RBC PS exposure, increased GSH levels and decreased the plasma concentration of free Hb 85 . A follow-up study focused on NAC's ability to reduce VWF activity suggested improvements in RBC parameters, decreased platelet adhesion and reduced VWF adhesive activity and protection against oxidative stress 86 . However, a randomized controlled phase III trial of NAC in patients with SCD did not provide any clinical benefit, although this was possibly owing to poor patient compliance 87 . Further studies are therefore warranted.
Anti-inflammatory agents.
Inflammation is a key factor in propagating and exacerbating the tissue injury caused by SCD. Essentially all cellular components of the immune system, including neutrophils, lymphocytes, monocytes and platelets, contribute to this process, and many pro-inflammatory cytokines are either chronically elevated or become acutely elevated in SCD. Therefore, various anti-inflammatory treatment approaches have been investigated. 89 . However, although infusion of regadenoson to adults with SCD decreased the activation of iNKT cells 90 , it was not sufficient to produce statistically significant changes in iNKT activation or in measures of clinical efficacy 91 . Production of TNF by monocytes and macrophages is an early response in ischaemia-reperfusion injury. The myriad of inflammatory responses mediated by TNF mirrors the sickle milieu, leading to vascular dysfunction and vaso-occlusion. Etanercept, a TNF receptor blocker, given long term to sickle mice, decreased vaso-occlusion, responses to painful agonists, monocyte activation, biomarkers of inflammation, liver injury and surrogate markers of pulmonary hypertension 92 . No human trials have been initiated to date, although a report of two cases of concomitant rheumatoid arthritis and SCD suggest that the drug can be safely used in SCD 93 . Intravascular haemolysis is a hallmark of SCD. Infusion of haem into SCD mice causes inflammation, microvascular stasis, pulmonary injury and death 44, 45 , and these adverse events can all be prevented by an antagonist of TLR4, TAK-242. Similar to TLR4, the complement system also contributes to SCD pathogenesis, in part owing to ischaemia-reperfusion physiology 94 . The alternative complement pathway is abnormally activated in SCD and is amplified by PS on the outer leaflet of SRBCs and microparticles 95 . PS on the surface of SRBCs and activated platelets accelerates the assembly of prothrombinase complexes, leading to thrombin generation, which can generate biologically active complement fragments 96, 97 . Recent studies suggest a role for antibodies to C5 that block microvascular stasis in sickle mice 98 . C5a receptor antagonists are also under development.
Invariant natural killer cells (iNKTs) contribute to inflammation that promotes vaso-occlusion and
Statins probably reduce cardiovascular events not only through cholesterol lowering but also through their anti-inflammatory effects. Simvastatin given to patients with SCD decreased expression of C-reactive protein, soluble ICAM1, soluble E-selectin and vascular endothelial growth factor (VEGF), and decreased frequency of pain 99, 100 . These preliminary data support a larger trial in SCD.
Levels of endothelin 1 (ET1), a potent vasoconstrictor, are increased in SCD 101 , and it plays a pro-inflammatory and pro-oxidative role. Endothelin receptor antagonists (ERAs) may provide a potent anti-inflammatory approach in SCD by blocking inflammatory polymorphonuclear neutrophils and lymphocytes and decreasing endothelial cell activation, and ERAs alter RBC membranes, cell adhesion, pain and hypoxia-induced death in SCD mice [102] [103] [104] [105] . Intravenous immunoglobulin (IVIG) has been shown to reverse vaso-occlusion in sickle mice 106 . IVIG can modulate neutrophil activation and vascular injury through FcγRIII and SHP1 (reF. 107 ). A single dose of IVIG can stabilize neutrophil MAC1 activation during sickle pain 108 , and a phase I/II trial of IVIG is underway for treating VOC (NCT01757418).
Phosphodiesterase 9 (PDE9) inhibitors block the degradation of cGMP and increase cellular cGMP levels. Increased cGMP is anti-inflammatory and has been shown to reduce the adhesion of leukocytes to the vascular endothelium 109 . In conjunction with hydroxyurea, the PDE9 inhibitor BAY73-6691 improved leukocyte rolling and decreased heterotypic RBC-leukocyte interactions in sickle mice, which was coupled with prolonged animal survival. In 35 patients with SCD, BAY73-6691 decreased levels of the inflammatory markers TNF and myelo peroxidase and increased levels of NO-containing species and the antioxidant enzyme superoxide dismutase 110 . The PDE9 inhibitor IMR-687 increased cGMP levels in K562 cells, and in sickle mice, IMR-687 decreased the percentage of SRBCs, increased HbF-positive cells and decreased microvascular stasis in response to hypoxia-reoxygenation 111 . Another PDE9 inhibitor, PF-04447943, was found to be safe in a phase I study (NCT02114203) in patients with SCD. Investigations of PDE9 inhibitors, as well as activators of soluble guanylate cyclase, such as riociguat (NCT02633397), continue to be enthusiastically pursued in order to increase cGMP levels, as does exploration of additional anti-inflammatory approaches to SCD.
Counteracting free Hb and haem. Haemolysis of SRBCs has several negative effects, including decreased NO bioavailability, increased oxidative stress, arginine depletion due to excess arginase and inflammation.
NO can vasodilate, inhibit platelets and alter inflammation, and it also plays a role in pulmonary hypertension. Various strategies to increase levels of NO have been explored in clinical trials in SCD (TaBle 4) , and some have shown promising effects. For example, arginine supplementation has been shown to have efficacy in leg ulcers and pain in SCD 112 . In an early clinical trial, there were no adverse effects from arginine, and narcotic use was decreased by >50% 113 . A current study (NCT02447874) is examining the role of supplemental arginine in the treatment of VOC in children. Hydroxyurea's beneficial effects in SCD in countering haemolysis-induced inflammation may also be mediated by NO through peroxidase-mediated formation of NO from hydroxyurea, hydrolysis of hydroxyurea to hydroxylamine and/or the NO-producing structure-activity relationships of hydroxyurea 114, 115 . In SCD, chronic haemolysis also depletes plasma haptoglobin and haemopexin. Studies in SCD mice 45, [116] [117] [118] suggest beneficial effects of supplementation, as co-infusion NATuRe RevIeWS | Drug DiSCOvery of human haptoglobin or haemopexin with Hb reduced vascular stasis, with these effects involving activation of NRF2 and HO1. Importantly, haptoglobin or haemopexin supplementation also inhibited VOC in unchallenged sickle mice, demonstrating the ongoing nature of haemolysis-driven VOC in SCD 45, 117, 118 . Although not currently available therapeutically as purified proteins, both haptoglobin and haemopexin are potentially extractable from human plasma for therapeutic interventions. Overall, approaches to reducing inflammation and oxidative injury remain among the most exciting new areas in drug development for SCD.
Anti-thrombotic therapies. In SCD, in which vascular occlusion, increased blood viscosity, activation of the coagulation system and endothelial injury and dysfunction promote thrombosis, anticoagulation has been long considered a potential therapeutic avenue. Coagulation activation occurs via multiple mechanisms in SCD: via TF-expressing and PS-expressing microparticles and abnormal exposure of PS on SRBCs and reticulocytes, erythrocyte-platelet and neutrophil-platelet aggregates in the circulation, endothelial cell activation and haemolysis itself 35, [119] [120] [121] . Increased thrombin (factor IIa) generation occurs in SCD, both by the activated contact pathway [122] [123] [124] [125] [126] [127] and the TF pathway, owing to aberrant and increased TF expression by monocytes and endothelial cells, which, together with its ligand factor VIIa, activates factor X (FX) 128, 129 . Activated factor X (FXa) results in generation of factor IIa from prothrombin (factor II) and increased fibrin generation.
Hence, lowering thrombin generation has long been a therapeutic target in SCD (TaBle 3) . Studies with warfarin and heparins beginning nearly 70 years ago have provided some initial indications of therapeutic activity [130] [131] [132] [133] , but warfarin is limited by its bleeding risk and heparins by the need for parenteral administration. With the advent of oral direct thrombin inhibitors (dabigatran) or factor Xa inhibitors (such as apixaban and rivaroxaban), these disadvantages of warfarin and heparin can be overcome. Indeed, apixaban and rivaroxaban are now in initial short-term clinical trials, the results of which await publication. Long-term use of these anticoagulant strategies may have the potential to ameliorate chronic organ damage on the basis of animal studies in which such an effect has been shown 36 .
Anti-platelet therapies. Platelet counts are higher in patients with SCD under steady-state conditions and further increase during VOC 21, 33 . Chronic platelet activation is observed in SCD 21, 33, 134 and is conceivably caused by increased circulating platelet agonists, such as thrombin, ADP and adrenaline, as well as increased platelet-monocyte and platelet-neutrophil aggregates. Activated platelets promote adhesion of SRBCs to the vascular endothelium and contribute to microthrombosis and pulmonary hypertension in SCD 33 . Thrombin activates platelets through proteolytic cleavage of two major protease-activated receptors, PAR1 and PAR4 (reFs 135, 136 ). Cell-free Hb, increased secondary to haemolysis, can also trigger platelet activation, and the bioavailability of NO, a key inhibitor of platelet activation, is reduced in SCD 33, 137 . Hence, a plethora of factors mediate platelet activation in SCD, and it has therefore been targeted to reduce acute events.
Preclinical studies with anti-platelet agents such as the P2Y 12 antagonist clopidogrel supported the possibility that blocking platelet activation and aggregation may be beneficial in SCD 39, [138] [139] [140] . However, clinical trials of anti-platelet therapies in SCD have yielded modest to disappointing results so far (summarized in TaBle 3 ). For example, several recent studies with the third-generation P2Y 12 antagonist prasugrel have been disappointing. Although no major bleeding complications were seen with prasugrel in four trials [141] [142] [143] [144] [145] , including one large randomized placebo-controlled multicentre trial 142 , these showed a nonsignificant decrease in VOCs despite significant platelet inhibition.
Overall, the studies summarized in TaBle 3 suggest that platelet activation does not play a major role in sickle cell acute VOC. Indeed, these studies are reminiscent of results observed in studies with anticoagulants, in which no clear benefit in acute events was evident. However, reducing thrombin generation chronically in SCD mice Box 2 | Challenges in drug development for sickle cell disease Preclinical drug development for sickle cell disease (SCD) has benefited from the creation of two murine models of SCD 216, 217 . Although neither faithfully mimics all aspects of SCD, many processes, such as vaso-occlusion and end-organ damage, can be studied reasonably well in these mice.
However, once a candidate drug is ready to enter clinical trials, there are several challenges. one is the many presentations of SCD, including acute pain, vaso-occlusive crises (voCs), chronic pain, fatigue, stroke, cognitive impairment, acute chest syndrome, pulmonary hypertension, cardiac dysfunction, nephropathy and leg ulcers, among others. The most common and devastating of these -acute pain episodes, stroke and acute chest syndrome -may arise from different processes, which are incompletely understood. In addition, there is no 'gold standard' or biomarker for identifying a voC, and diagnosis of an event as well as definition of its resolution therefore rely on patient-reported symptoms.
Thus, choosing both a therapeutic end point (for example, prevention or amelioration of acute vaso-occlusion) and then deciding how to define the end point and what change in the end point is clinically meaningful can be difficult. Some of the end points considered in recent clinical trials designed to achieve prophylaxis end points have been reduction in rate of hospitalization, rate of voC, frequency of acute chest syndrome, degree of chronic pain, analgesic usage, rate of red blood cell transfusion due to SCD, school absence and incidence of stroke. Drugs designed to improve acute pain episodes have generally defined end points such as length of pain crises, time to resolution from start of therapy or length of hospitalization for voC. most of these end points, however, are made more difficult to analyse by the extreme heterogeneity that characterizes SCD. Not only are there different types of SCD (for example, homozygosity for haemoglobin S (HbS) or compound heterozygosity for HbS and haemoglobin C (HbC)), but even within specific genetic types, measures such as frequency and length of painful episodes are quite variable.
In addition, without well-established evidence-based guidelines, there is abundant institutional heterogeneity in day-to-day and acute event management of patients. Although heterogeneity can be overcome by enrolment of a large number of subjects, that is also hard to achieve in SCD. With <100,000 patients with SCD in the united States and <15,000 in the united Kingdom but millions in Africa and India, the resources and skills needed to conduct clinical trials are geographically mismatched with the potential subjects. even in the united States, many centres with hundreds of patients with SCD have few resources available to conduct clinical trials well. overall, these factors make conduct and successful completion of clinical trials in SCD difficult, although a number of phase II studies have recently met their targeted enrolment and been successfully completed 147, 148, 218 . most of these have used frequency and/or length of acute painful episodes as their primary end point for judging efficacy, as did the multicentre Study of Hydroxyurea two decades ago 219 .
www.nature.com/nrd led to a remarkable improvement in multi-organ pathologies and improved survival 36 . An early clinical report showed no difference in acute VOCs with prolonged use of the anticoagulant dicumarol, but healing of leg ulcers was observed, suggesting that chronic anticoagulation or anti-platelet therapy remain worthy of investigation with organ damage as the end point of study rather than VOCs 131 . None of these anti-platelet studies have addressed the potential effects of chronically reducing platelet activation and the implications for long-term organ damage, which remains a major cause of death in SCD despite improvements in preventive care. In addition, anti-platelet therapy is usually best at preventing arterial complications, and in SCD, these conditions (stroke, pulmonary hypertension or priapism) have not been studied in SCD trials with anti-platelet agents.
Anti-adhesion agents. Considerable progress has been made with anti-adhesion agents for SCD, and drugs that interfere with selectin-mediated adhesion currently appear the most promising in this area. Selectins are expressed by endothelial cells as well as all circulating blood cells except erythrocytes. Receptors for selectins are present on all blood cells, including erythrocytes. In general, selectins mediate fast-on-fast-off cell-cell interactions and therefore facilitate 'rolling' , a phenomenon in which cells have intermittent or even continuous contact with endothelial cells as they traverse the circulation. Furthermore, these interactions lead to firmer attachment through integrin-mediated interactions, resulting in stable attachment and, in the case of leukocytes, migration of the cells through the endothelial layer into tissues in the presence of appropriate chemokine signals. However, it remains unclear whether E-selectin or P-selectin is most important to the pathophysiological mechanism of vaso-occlusion. Animal studies to date are somewhat conflicting, with at least some suggesting that both are important 24, 146 . TaBle 5 summarizes the anti-adhesion agents that have been tested clinically. Thus far, three pharmacological inhibitors of selectin-mediated adhesion have been or are in human clinical trials. Rivipansel (formerly known as GMI-1070) is a small-molecule pan-selectin inhibitor that requires intravenous infusion and has the strongest activity against E-selectin. After completion of a successful phase II study (NCT01119833), in which the drug markedly reduced opioid requirements during VOC 147 , a phase III randomized placebo-controlled multicentre study of the drug for vaso-occlusive episodes (NCT02187003) was undertaken and is now well underway.
Crizanlizumab is a humanized monoclonal antibody that solely inhibits P-selectin, and it also requires intravenous infusion. A phase II study of monthly infusions of this drug for the prevention of vaso-occlusion (NCT01895361) was recently concluded and showed, at the highest dose used, a significant reduction in VOCs requiring hospitalization, although without a significant effect on quality of life 148 . There is also an ongoing phase II trial of another P-selectin blocker, sevuparin, which is a heparinoid derivative that retains P-selectin binding ability but has almost no anticoagulant effect. This compound was effective in reducing vaso-occlusion after inflammatory stimuli in a mouse model 149 , and it has also been safely tested in a phase II study of malaria 150 . Tinzaparin was used successfully for VOCs in a phase II study 133 , although whether its effect was attributable to its anticoagulant activity or its P-selectin-blocking activity is not clear. A sulfated non-anticoagulant version of tinzaparin has also been shown to reduce SRBC adhesion to endothelial cells 151 
.
As noted above, although selectins mediate early adhesive events, they do not cause firm adhesion, which is the province of integrins. SRBCs bind firmly to endothelial cells largely through binding to endothelial αvβ3 integrin 152 , the erythroid ligand of which is ICAM4 (LW blood group antigen protein) 17, 153 . However, although at least one FDA-approved drug (abciximab) blocks both this interaction and SRBC interactions with the platelet integrin αIIbβ3, it remains to be studied in patients with SCD, perhaps owing to the profound platelet dysfunction associated with this drug.
Interestingly, however, the erythroid ICAM4 protein, as well as several other erythroid adhesion receptorsLu/BCAM (the RBC laminin receptor) and CD44 (the RBC hyaluronan and α4β1 integrin receptor) -are activatable via erythroid signalling pathways involving β 2 -adrenergic receptors 17, 42, 153, 154 and the MAPK pathway 18 . Indeed, the beta-blocker propranolol, which effectively blocks both adrenaline and TNF-induced vaso-occlusion in vivo in mice, has been studied in phase I and phase II trials 155, 156 . However, to date, no investigator or pharmaceutical company has proposed testing of propranolol in a randomized, placebocontrolled phase III study. Likewise, MEK inhibitors, some of which are FDA-approved drugs, can also prevent vaso-occlusion in murine models by downregulating both SRBC and leukocyte adhesion 157, 158 , but human trials in SCD have thus far not been undertaken.
Agents that address specific end-organ damage. Given the complex pathophysiology of SCD, there are many potential pathways by which individual organ processes might be addressed (TaBle 6) . However, mortality in SCD is closely tied to three acute and chronic organ damage syndromes: ACS, pulmonary hypertension and sickle cell nephropathy 5, [159] [160] [161] [162] [163] [164] . ACS remains the most common acute event leading to mortality in both children and adults with SCD. ACS typically presents with hypoxaemia and pulmonary infiltrates consistent with pneumonia on chest radiography. This syndrome can have a rapid downhill course, which may result from the effect hypoxia has on the pulmonary endothelium, including upregulation of adhesion molecules and downregulation of protective mechanisms, such as NO 165 . Recently, in its approval of l-glutamine, the FDA cited not only its ability to reduce the frequency of VOC but also its efficacy in reducing the incidence of ACS 166 . Levels of secretory phospholipase A2 (sPLA2) often rise during the period preceding onset of ACS during a vaso-occlusive event 167 . Varespladib (A-001), an inhibitor of sPLA2, is theorized to act as an antiinflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. However, studies of varespladib to treat ACS have not proved successful, including a phase III trial that was terminated owing to lack of efficacy. Other approaches to treatment of ACS have included inhaled NO 168 , which appeared to have benefited patients with hypoxaemia in a post hoc analysis, and, in an ongoing study, l-citrulline (NCT02697240) 169 . Steroids have also been studied as a treatment for or to prevent recurrence of ACS [170] [171] [172] , although concern about rebound pain and other side effects has prevented wide adoption of this approach.
Pulmonary artery hypertension is a chronic condition also associated with premature mortality in SCD.
In adults with sickle cell anaemia (two β S alleles or one β S allele and one β 0 allele), very mild elevations of tricuspid regurgitant jet velocity (>2.5 m s -1 ) that reflect only modestly increased pulmonary artery pressures that would be clinically unimportant in other settings are strongly linked to increased mortality. SCD is associated with markedly increased plasma levels of both ET1 and ET3. ERAs, such as bosentan, have been proposed to have therapeutic value in this setting and are sometimes used to treat pulmonary hypertension in SCD. In an animal model of SCD, bosentan prevented vascular congestion, systemic inflammation and infiltration of activated neutrophils in both the lungs and kidneys after a hypoxia-reoxygenation challenge 173 . A small nonrandomized prospective study of bosentan and ambrisentan has shown some promise in severely affected patients with SCD with pulmonary hypertension 174 . Unfortunately, randomized, double-blinded studies of bosentan failed to accrue adequately to judge efficacy 175 . Sickle cell nephropathy affects nearly 30% of adults with HbSS or HbSβ 0 -thalassaemia 5, [176] [177] [178] . Angiotensinconverting enzyme inhibitors have been proposed and studied for the treatment of proteinuria in SCD, as in diabetic and other nephropathies involving protein uria. In many centres, such therapy is common practice, although strong evidence for efficacy of this approach is lacking 179 . More recently, angiotensin receptor blockers, such as losartan, have also been considered for sickle cell nephropathy, and a prospective phase II trial has shown that it reduces microalbuminuria and macroalbuminuria without adverse events 180, 181 . Overall, most efforts to develop new treatments for SCD are focusing on the systemic pathophysiological processes responsible for both pain and end-organ damage, such as SRBC sickling, oxidative damage, cell adhesion, inflammation and coagulation. It is hoped that ameliorating these widespread phenomena will be effective in preventing much of the end-organ damage. Nonetheless, developing drugs that can specifically address injurious organ-specific processes remains an important avenue of drug development given that these cause the vast majority of SCD-related deaths in resource-rich settings such as Western Europe and the United States.
Gene therapy. Gene therapy to correct autologous HSCs could also be an attractive curative option, as it would overcome the obstacle of finding a matched donor needed for HSC transplantation and be devoid of immune complications associated with an allogeneic transplant, such as graft-versus-host disease or graft rejection. 182, 183 . Hence, genetic modification of a fraction of HSCs may suffice as a one-time treatment for SCD. On the basis of the potent anti-sickling properties of HbF noted above, gene therapy strategies are being pursued either to express γ-globin in postnatal RBCs or reactivate endogenous γ-globin expression. Preclinical studies of additive gene therapy have shown that even <20% genemodified HSC chimaerism is beneficial in improving organ pathology and prolonging life significantly 183 , an effect akin to the heterocellular expression of HbF with hydroxyurea.
Gene addition strategies that have reached clinical trials utilize lentiviral vectors to deliver an erythroidspecific anti-sickling gene. Lentiviral vectors can readily transfer therapeutic genes into the fairly quiescent HSCs at very high efficiency 184, 185 and have shown clinical efficacy and safety in a number of genetic disorders [186] [187] [188] [189] [190] [191] [192] . The downside of this approach is that the gene and the appropriate promoter and regulatory elements have to be delivered via the vector, which integrates semi-randomly into the genome. There is therefore a potential of genotoxicity due to inadvertent dysregulation of a cellular gene. Importantly, however, a decade-long clinical trial experience has not shown genotoxicity of lentiviral vectors in patients.
Although anti-sickling globins have the potential to greatly ameliorate disease, patients still make HbS; hence, even if 'cured' of SCD symptoms and organ damage, they are not genetically cured of SCD. Nevertheless, preclinical studies with anti-sickling globins have shown complete correction of the SCD phenotype owing to a large selective advantage of HbFcontaining sickle erythrocytes over uncorrected ones, and a 20-40% gene-modified HSC chimaerism results in a near pan-cellular F-cell production. Three versions of non-sickling or anti-sickling genes are being used in erythroid-specific lentiviral vectors in three clinical trials for SCD: NCT02140554, utilizing a β-globin-derived gene (β T87Q ) that prevents sickle Hb polymerization 190, 193 ; NCT02247843, utilizing a β-globin gene (βAS3) with three point mutations that confer anti-sickling properties [194] [195] [196] ; and NCT02186418, utilizing a γ-globin coding sequence embedded in a β-globin gene 183 . Thus far, one phenotypic cure has been reported from the use of β T87Q lentiviral vector 190 , and other results are awaited. Using recent advances in gene editing, it is now also possible to develop therapies that achieve precise genetic modifications in a patient's HSCs ex vivo 197, 198 . This has the major advantage of being a highly targeted approach to the gene of interest. Furthermore, if the endogenous gene can be fixed, it would be regulated naturally by the www.nature.com/nrd endogenous promoters and enhancers. There would be no random integration of vector DNA. The key disadvantage is that gene-editing strategies typically make a targeted DNA double-strand break (DSB) but rely on the cell to repair this break. By far, the most common mode of DSB repair is non-homologous end joining, often resulting in gene disruption or knockout. In the presence of a homologous donor template, a fraction of cells repair the DSB via homologous recombination, a precise repair mechanism and the more clinically desirable outcome 199 . Intensive efforts to improve homologous recombination frequency in HSCs via gene editing are currently underway [200] [201] [202] [203] [204] . Second, site-directed nucleases can have off-target activity, creating DSBs at unintended sites 205, 206 . These hurdles are currently being tackled by researchers in order to translate gene editing to the clinic. Thus far, two major approaches are being actively investigated. The first is derepression of the γ-globin gene by either knocking out its repressor, BCL-11A 207, 208 , or putative binding sites for γ-globin repressors 209 . The second is genetic correction of the β S mutation by providing a homology template with the correct sequence at the sixth codon 194, 197, 210 . Correction of the β S mutation, if at sufficient levels, would indeed be a 'cure' of SCD.
However, although specific gene knockouts using these approaches can be achieved quite efficiently in a large proportion of HSCs and progenitor cells, precise gene correction in long-term repopulating cells is still inefficient 197, 201, 210, 211 . Moreover, gene editing results in significant loss of the HSC long-term repopulating potential 194, 197, 210 . Hence, gene correction technologies are at a preclinical stage for the treatment of SCD.
One rate-limiting hurdle for gene therapies is difficulty in obtaining adequate numbers of HSCs from patients with SCD, who cannot tolerate mobilization of HSCs via the conventional GCSF-mediated mobilization. Thus, bone marrow harvest is the predominant way of obtaining HSCs in SCD, and limited numbers of HSCs can be obtained via this route. Trials of the use of plerixafor to mobilize HSCs are underway (NCT02989701, NCT02193191, NCT02212535 and NCT03226691), and preliminary results show that this may be safe and feasible [212] [213] [214] . Another hurdle to successful gene therapies in general is ensuring that genetically manipulated HSCs retain long-term repopulating potential, as major losses in HSC potential occur with in vitro culture and manipulation. A third hurdle for gene therapies in SCD is the toxicity/morbidity associated with pre-transplant conditioning. Reduced-intensity pre-transplant conditioning is being clinically tested for gene therapy for SCD (NCT02186418). Antibodymediated non-chemotherapy conditioning is currently being tested for severe combined immune deficiency transplants (NCT02963064), and advancements in this technology may make it useful in SCD in the future. Progress on these three major challenges will go a long way to making gene therapy more easily applicable and transportable, increasing the potential for application, including in resource-poor countries. Finally, closedsystem automated gene transfer systems that have been developed to transfer chimeric antigen receptors into T cells for cancer immunotherapy could ease the gene transfer process for SCD therapies.
Time for multi-agent therapy for SCD As described above, a complex network of intertwined and interdependent processes results from the A to T substitution in the β-globin gene that produces HbS. The optimal therapeutic strategy would eliminate this genetic alteration in the RBCs and solve the downstream consequences of vaso-occlusion, anaemia and haemolysis. However, HSC transplantation is the only currently available strategy capable of achieving this goal, and it is expensive, limited to a small group of patients and has substantial safety risks. Gene therapy also holds the potential to be curative but is at an early stage of development, with substantial technical challenges, and is likely to be very costly, at least initially. The high cost and the technical challenges mentioned above are likely to strongly limit the potential for application in resourcepoor countries with high numbers of people affected by SCD, at least in the near future.
Therefore, although the hurdles associated with curative therapies are being overcome, we propose that a multi-agent systems-oriented approach has the potential to greatly improve outcomes for patients with SCD more broadly. As described above, the use of hydroxyurea, which inhibits HbS polymerization by inducing HbF, has been very effective in altering the course of SCD for many patients. However, despite higher HbF levels, patients still suffer debilitating VOCs, strokes, organ dysfunction and pain. Moreover, therapies targeted at different pathophysiologies have shown modest effect. We therefore ask the following question: can we take the approach commonly used in cardiology, oncology and HIV therapy and utilize multiple agents from among the types described above to more effectively alter the interconnected processes and ultimately the course of SCD, thus improving the quality and length of life for patients? What would such a cocktail look like? Which processes should be targeted? At what age should this approach begin -infancy, childhood, adulthood or before organ damage? Can the toxicity of adding multiple drugs be tolerated? Would more complicated regimes and greater 'pill burden' hamper compliance with therapy? Will host defences be dangerously compromised, leading to infections and autoimmunity? Should there be a separate cocktail for acute events versus chronic therapy?
So far, three leading drug candidates for SCD in latestage development -crizanlizumab, rivipansel and voxelotor (GBT-440) 147, 148, 215 -have all been shown to have positive effects in the presence or absence of hydroxyurea. If any were to receive final approval, they -similar to l-glutamine -would probably be used either without or added to hydroxyurea and would be likely to have at least somewhat additive benefits. If approved, these could also become important 'building blocks' in the assembly of multi-agent treatment regimens, which might include different medications to be used in prophylactic or acute treatment settings (Fig. 3) .
Although anticoagulants, anti-platelet agents and agents with anti-inflammatory effects such as prasugrel and regadenoson have so far not shown clear benefit when used alone or with hydroxyurea, drugs of these classes may nonetheless provide incremental benefit when used with drugs targeting other pathophysiological processes. Strategically, the order of addition of each agent to treat a specific patient may be guided by the previous response, with defined end points for each, such as HbF content or Hb p50; markers of oxidative stress or inflammation; WBC, RBC, platelet and reticulocyte count; markers of haemolysis; plasma Hb, haptoglobin and haemopexin levels; frequency of VOC; duration of pain crises; and quality-of-life measures. For example, combining an anti-sickling agent with a scavenger of haem and Hb to address sickling and haemolysis could be attempted. An anti-thrombotic, antioxidant, antiadhesive or anti-inflammatory agent could then be added to one or both of these, together or sequentially, and different combinations could be compared. Clinical trials would need to be developed on the basis of preclinical studies and rigorous planning in order to best discover additive or synergistic effects given the limited patient populations available and the costs of such trials. Biomarkers of pathophysiological activation of various pathways may also help steer therapeutic approaches and should be examined for correlation with clinical responses. To date, however, biomarkers of short-term disease activity have been disappointing. Although there are obvious barriers to such an approach, we feel that they can potentially be overcome. The health of millions of patients with SCD depends upon the success of such an endeavour. 
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